| HOME >> MEDICINE >> TECHNOLOGY |
"This patient variability has been under-recognized, in part due to lack of practical ways to evaluate it," continues Wider. "Current methods require monitoring of intracranial pressure involving invasive access to the brain, or are not designed for continuous monitoring, and therefore are not routinely used. This new approach involving the INVOS System provides continuous data on cerebral autoregulation without intracerebral pressure monitoring so physicians can readily define each patient's requirements and optimize blood pressure to improve outcomes."
Increasing awareness of patient variability in autoregulation is fueling discussions on patient-specific blood pressure targets and management techniques. Data supporting Brady's cerebral autoregulation technology will be presented at the American Society of Anesthesiologists (ASA) annual conference this month. In addition, the Anesthesia Patient Safety Foundation is hosting a physician workshop related to the topic of autoregulation prior to the ASA, and also dedicated its Spring/Summer 2009 newsletter to it.
About Somanetics
Somanetics Corporation (Nasdaq: SMTS) develops, manufactures and markets the INVOS(®) Cerebral/Somatic Oximeter which noninvasively provides accurate, real-time blood oxygen measurements in patients greater than 2.5 kilograms, and trend monitoring of this parameter for individuals of any weight. The INVOS System is the only commercially-available cerebral/somatic oximeter proven to improve outcomes. Surgeons, anesthesiologists and other medical professionals can use data provided by the INVOS System, i
'/>"/>
| SOURCE Somanetics Corporation Copyright©2009 PR Newswire. All rights reserved |